Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GARP monoclonal antibody JYB 1907

A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GARP monoclonal antibody JYB1907 selectively targets and binds to GARP. This specifically blocks the GARP-mediated release of the cytokine transforming growth factor-beta 1 (TGF-b1), thereby relieving the immunosuppression caused by TGF-b1 and reversing the immunosuppressive nature in the tumor microenvironment (TME). This improves anti-tumor immune responses GARP, a transmembrane protein highly expressed on activated, immunosuppressive regulatory T cells (Tregs) in the TME, is essential for the expression of TGF-b1 on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function and the immunosuppressive nature of Tregs. TGF-b1 stimulates stromal cell proliferation, neovascularization, cancer cell metastasis, and inhibits immune cell infiltration.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-glycoprotein A repetitions predominant monoclonal antibody JYB1907
Code name:JYB 1907
JYB-1907
JYB1907
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search